Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD) - Contacts and Locations

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

This study is currently recruiting participants.

Study NCT00568594. Last updated on June 17, 2008. Information provided by Novartis

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568594

Contacts


Contact: NOVARTIS	+41 61 324 1111

Locations


United States, Pennsylvania
	Novartis Investigator Site	Recruiting
	Philadelphia, Pennsylvania, United States
	Contact: Novartis 862-778-8300

Belgium
	Novartis Investigator Site	Recruiting
	Antwerp, Belgium
	Contact +41 61 324 1111
	Novartis Investigator Site	Recruiting
	Leuven, Belgium
	Contact: Novartis +41 61 324 1111

Denmark
	Novartis Investigator Site	Recruiting
	Birkenrod, Denmark
	Contact: Novartis +41 61 324 1111

Israel
	Novartis Investigator Site	Recruiting
	Tel-Aviv, Israel
	Contact: Novartis +41 61 324 1111

Netherlands
	Novartis Investigator Site	Recruiting
	Groningen, Netherlands
	Contact +41 61 324 1111

South Africa
	Novartis Investigator Site	Recruiting
	Bloemfontein, South Africa
	Contact: Novartis +41 61 324 1111

United Kingdom
	Novartis Investigator Site	Recruiting
	Harrow, United Kingdom
	Contact +41 61 324 1111

Sponsors and Collaborators

Novartis

Investigators


Principal Investigator:	NOVARTIS	Novartis investigative site